Several brokerages have updated their recommendations and price targets on shares of Johnson & Johnson (NYSE: JNJ) in the last few weeks:

  • 9/1/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $145.00 price target on the stock.
  • 8/31/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $148.00 price target on the stock.
  • 8/24/2017 – Johnson & Johnson was given a new $147.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 8/24/2017 – Johnson & Johnson had its “underweight” rating reaffirmed by analysts at UBS AG.
  • 8/16/2017 – Johnson & Johnson had its price target raised by analysts at J P Morgan Chase & Co from $140.00 to $148.00. They now have an “overweight” rating on the stock.
  • 8/15/2017 – Johnson & Johnson was given a new $145.00 price target on by analysts at Jefferies Group LLC. They now have a “hold” rating on the stock.
  • 8/4/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Credit Suisse Group.
  • 7/31/2017 – Johnson & Johnson was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “J&J reported mixed Q2 results, beating on earnings but missing on sales. Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition. However, J&J is optimistic that sales growth will accelerate in 2H17. We believe that new products including Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH. J&J’s shares have outperformed the large-cap pharma industry this year so far. However, headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment due to category slowdown is also a concern.”
  • 7/27/2017 – Johnson & Johnson was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $148.00 price target on the stock. According to Zacks, “J&J reported mixed Q2 results, beating on earnings but missing on sales. Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition.  However, J&J is optimistic that sales growth will accelerate in 2H17. Though headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain, we believe that new products including Xarelto, Stelara, Darzalex, and Imbruvica remain the key to J&J’s growth. Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH. J&J’s shares have outperformed the industry this year so far. However, sluggish growth in the Consumer segment due to category slowdown is a concern.”
  • 7/21/2017 – Johnson & Johnson was downgraded by analysts at BTIG Research from a “neutral” rating to a “sell” rating. They now have a $110.00 price target on the stock.
  • 7/21/2017 – Johnson & Johnson was downgraded by analysts at Atlantic Securities from a “neutral” rating to an “underweight” rating. They now have a $113.00 price target on the stock.
  • 7/21/2017 – Johnson & Johnson was downgraded by analysts at Alembic Global Advisors from a “neutral” rating to an “underweight” rating.
  • 7/21/2017 – Johnson & Johnson was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “J&J reported mixed Q2 results, beating on earnings but missing on sales. Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition. However, J&J is optimistic that sales growth will accelerate in 2H17. We believe that new products including Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH. J&J’s shares have outperformed the large-cap pharma industry this year so far. However, headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment due to category slowdown is also a concern.”
  • 7/20/2017 – Johnson & Johnson is now covered by analysts at Credit Suisse Group. They set an “outperform” rating and a $148.00 price target on the stock.
  • 7/19/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $148.00 price target on the stock, up previously from $136.00.
  • 7/14/2017 – Johnson & Johnson had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $145.00 price target on the stock, up previously from $140.00.
  • 7/12/2017 – Johnson & Johnson was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/12/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $138.00 price target on the stock.

Shares of Johnson & Johnson (NYSE JNJ) traded up 0.71% on Wednesday, reaching $130.82. 1,641,836 shares of the company’s stock were exchanged. The company has a market capitalization of $351.12 billion, a P/E ratio of 22.14 and a beta of 0.79. The stock’s 50-day moving average price is $132.83 and its 200-day moving average price is $128.69. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same period in the previous year, the firm earned $1.74 EPS. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.59%. Johnson & Johnson’s payout ratio is currently 56.76%.

In related news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.